Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study)
A randomized trial of concurrent recombinant tissue-type plasminogen activator (r-tPA) + thrombin-inhibition with Argatroban in stroke patients recently demonstrated safety and signal of efficacy compared to r-tPA alone, but patients having endovascular therapy (EVT) were excluded. The current study intended to study feasibility and safety of concurrent r-tPA and Argatroban in pa tients undergoing EVT.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Ketevan Berekashvili, Jazba Soomro, Loren Shen, Vivek Misra, Peng R. Chen, Spiros Blackburn, Mark Dannenbaum, James C. Grotta, Andrew D. Barreto Source Type: research